Der hier verfügbare Newsfeed wird von unserem Content-Partner PR Newswire bereitgestellt. Es handelt sich dabei um einen der bedeutendsten und reichweitenstärksten Pressedienste, die Nachrichten, Pressemitteilungen und Multimedia-Inhalte an Medien, Journalisten und der Öffentlichkeit zur Verfügung stellen.
Der NewsWire-Hub ("X-Billboard") umfasst derzeit vier der wichtigsten internationalen Nachrichtenquellen und wird durch einen Börseninformationsservice ergänzt. Die einzelnen Newswire-Services ergänzen sich und bilden ein komplementäres Informationsangebot, mehr als drei Viertel der offiziellen Nachrichtenquellen ab, auf die sich Redaktionen weltweit bei ihrer Börsenberichterstattung stützen. Ihr Vorteil: Sie finden hier alles in einer Übersicht. Über die Steuerelemente können Sie zu den einzelnen Bereichen navigieren. Im Terminalview können Sie gezielt auf Unternehmensebene individuelle Recherchen durchführen.
Systemstatus: 39.362 Nachrichten wurden bislang erfolgreich verarbeitet
PR Newswire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
US28176E1082
Letzte Aktualisierung: 17.08.2024 | 11PM
Kennen Sie bereits den neuen Terminal-View? Folgen Sie bei Interesse dem folgenden Link.
FIGI: BBG000BRXP69
EW

Edwards Lifesciences Corporation
GICS: - · Sektor: Healthcare · Sub-Sektor: Medical Devices
NAME
Edwards Lifesciences Corporation
ISIN
US28176E1082
TICKER
EW
MIC
XNYS
REUTERS
EW.N
BLOOMBERG
EW US
Sa., 16.11.2024       Edwards Lifesciences

RADNOR, Pa., Nov. 16, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period")  The lead plaintiff deadline is December 13, 2024.

Sa., 16.11.2024       Edwards Lifesciences

LOS ANGELES, Nov. 15, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW).

Class Period: February 6, 2024 – July 24, 2024Lead Plaintiff Deadline: December 13, 2024

If you wish to serve as lead plaintiff of the Edwards Lifesciences lawsuit, you can submit your contact information at www.glancylaw.com/cases/edwards-lifesciences-corporation/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

Fr., 15.11.2024       Edwards Lifesciences

NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team:

Fr., 15.11.2024       Edwards Lifesciences

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 14, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) and reminds investors of the December 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Do., 14.11.2024       Edwards Lifesciences

SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"), have until Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards Lifesciences as well as certain of Edwards Lifesciences' executives with violations of the Securities Exchange Act of 1934.

Do., 14.11.2024       Edwards Lifesciences

NEW YORK, Nov. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW).

Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

Mi., 13.11.2024       Edwards Lifesciences

LOS ANGELES, Nov. 13, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE: EW) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mi., 13.11.2024       Edwards Lifesciences

NEW YORK, Nov. 12, 2024 /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"), of the important December 13, 2024 lead plaintiff deadline.

So what: If you purchased Edwards Lifesciences Corporation securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Di., 12.11.2024       Edwards Lifesciences

BENSALEM, Pa., Nov. 12, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW).

Class Period: February 6, 2024 – July 24, 2024Lead Plaintiff Deadline: December 13, 2024

Investors suffering losses on their Edwards Lifesciences investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 215-638-4847 or by email to howardsmith@howardsmithlaw.com.

Di., 12.11.2024       Edwards Lifesciences

NEW YORK, Nov. 12, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team:

Mo., 11.11.2024       Edwards Lifesciences

NEW YORK, Nov. 11, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW).

Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

So., 10.11.2024       Edwards Lifesciences

RADNOR, Pa., Nov. 10, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is December 13, 2024.

So., 10.11.2024       Edwards Lifesciences

SAN DIEGO, Nov. 8, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), have until Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit.  Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards Lifesciences as well as certain of Edwards Lifesciences' executives with violations of the Securities Exchange Act of 1934.

Fr., 08.11.2024       Edwards Lifesciences

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 8, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) and reminds investors of the December 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Fr., 08.11.2024       Edwards Lifesciences

LOS ANGELES, Nov. 8, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE: EW) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Do., 07.11.2024       Edwards Lifesciences

LOS ANGELES, Nov. 7, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW).

Class Period: February 6, 2024 – July 24, 2024Lead Plaintiff Deadline: December 13, 2024

If you are a shareholder who suffered a loss, click here to participate.

Do., 07.11.2024       Edwards Lifesciences

NEW YORK, Nov. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW).

Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

Di., 05.11.2024       Edwards Lifesciences

SAN DIEGO, Nov. 5, 2024 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), have until Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit.  Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards Lifesciences as well as certain of Edwards Lifesciences' top executives with violations of the Securities Exchange Act of 1934.

Di., 05.11.2024       Edwards Lifesciences

NEW YORK, Nov. 5, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team:

Mo., 04.11.2024       Edwards Lifesciences

LOS ANGELES, Nov. 4, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE: EW) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Die hier zur Verfügung gestellten Informationen unterliegen keiner redaktionellen Bearbeitung. Die Aufbereitung erfolgt vollautomatisch und wird durch Zusatzinformationen und weiterführende Recherchemöglichkeiten angereichert. Ziel der Inhalte ist die schnelle und unkomplizierte Versorgung der Informationssuchenden mit den für sie relevanten Informationen. Durch eine Rückverlinkung auf den Informationsanbieter und -eigentümer ist sichergestellt, dass die hier aufbereiteten Daten bei Bedarf mit den Quellinformationen abgeglichen werden können. Das Newsboard zeigt keine Informationen in Echtzeit. Diese bitten wir bei Bedarf beim Börsenbetreiber abzurufen. Es besteht kein Anspruch auf Vollständigkeit. Hochverfügbarkeit kann nicht gewährleistet werden. Sollten Sie Fehler in der Funktionsweise bemerken, teilen Sie uns diese über das weiter unten befindliche Formular "Report a Bug" mit.

RAW DATA PROCESSING bedeutet, dass Rohdaten verarbeitet werden, ohne den Inhalt zu verändern. Um die Interpretation der Information im Sinne der Nutzbarkeit zu verbessern, werden die Daten ergänzt. 

Hinweis: Über das Newswire-Crosslink-Panel im oberen Bereich gelangen Sie schnell und bequem zu weiteren Informationsquellen. Im Terminalview sind die Nachrichten auf Unternehmensebene gefiltert und ermöglich darüber gezielte Recherchen.


Wir bedanken uns im Namen der Trading-Community bei den Betreibern der Handelsplätze für die Bereitstellung von Informationsdiensten.